A new analysis of publicly reported financial data by researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health finds that large, brand-name drug manufacturers would still be the most profitable industry sector even
WASHINGTON, D.C. – Employers’ Prescription for Affordable Drugs (EmployersRx) issued this statement in conjunction with the ongoing debate of the Lower Drug Costs Now Act of 2019 (H.R. 3), the Prescription Drug Pricing Reduction Act
When it comes to lowering skyrocketing drug prices, employers are making their voices heard on drug price transparency, drug price increase caps, and other price reducing strategies through the new coalition Employers' Prescription for Affordable Drugs (EmployersRx).
H.R. 3, a drug-price proposal from Democrats in Congress, would save taxpayers $345 billion over a seven-year period, according to a new estimate by the Congressional Budget Office. Read the story on Bloomberg >
Employers’ Prescription for Affordable Drugs uniting to advance competition, transparency and value WASHINGTON, D.C., October 09, 2019 – The Pacific Business Group on Health (PBGH), The ERISA Industry Committee (ERIC) and the National Alliance of